Many individuals report that rheumatoid arthritis appears suddenly, with some experiencing painful, swollen joints, extreme fatigue, and stiffness that interfere with daily routines.
However, researchers now understand that the disease often begins developing long before any diagnosis is made.
A recent study from King’s College London indicates that early intervention might greatly postpone the onset of rheumatoid arthritis. Published in The Lancet Rheumatology, the study found that a year-long treatment with the drug abatacept delayed rheumatoid arthritis in those at high risk.
This research is particularly significant because there are currently no approved treatments aimed specifically at preventing rheumatoid arthritis. Most therapies are administered after the disease has already caused joint damage.
Rheumatoid arthritis is an autoimmune disorder. In autoimmune conditions, the immune system mistakenly attacks healthy tissues instead of defending the body from infections.
With rheumatoid arthritis, the immune system primarily targets the joints, leading to inflammation, pain, swelling, and stiffness. Prolonged inflammation can damage cartilage and bones, ultimately causing disability and lowering quality of life.
The condition affects hundreds of thousands in the U.S. and millions globally. While it can occur at any age, it typically develops during middle age. Many individuals endure years of pain, fatigue, and difficulty performing everyday tasks or working.
Scientists have recently started focusing on identifying people who are likely to develop rheumatoid arthritis before symptoms become severe.
Certain blood tests detect antibodies that can appear years prior to diagnosis. These serve as warning signs that the immune system might be heading in the wrong direction.
The study tracked 213 participants from the U.S. and the Netherlands, all considered at high risk of developing rheumatoid arthritis. Some received abatacept for a year, while others received a placebo.
Abatacept is a biologic medication that modulates immune activity. It’s already approved for treating established rheumatoid arthritis, but researchers wanted to explore whether it could be effective earlier in the disease process.
The original trial lasted two years, but the new research extended follow-up to between four and eight years, making it one of the longest studies of its kind in high-risk individuals.
The results showed promising trends. Participants on abatacept developed rheumatoid arthritis much later than those on placebo. In some cases, the delay was up to four years after stopping treatment.
While abatacept didn’t fully prevent the disease, postponing its onset by several years could have meaningful benefits, such as less pain, reduced disability, and fewer disruptions to work and family life.
The biggest benefits were observed in participants at the highest risk, identified through blood tests detecting disease-related antibodies. Interestingly, those most likely to develop rheumatoid arthritis also gained the most from treatment.
Participants reported improvements in symptoms—including joint pain, fatigue, and overall wellbeing—during treatment. However, these benefits tended to diminish after stopping the medication, suggesting continuous treatment might be necessary to sustain symptom relief.
The study also confirmed that the treatment is relatively safe, with serious side effects occurring at similar rates in both the abatacept and placebo groups. No new safety concerns emerged during long-term follow-up.
This research offers compelling evidence that autoimmune diseases can potentially be modified before they fully manifest. The extended follow-up strengthens the findings, showing that some benefits may persist even after treatment stops.
However, since abatacept only delayed rather than prevented rheumatoid arthritis, additional studies are needed to determine whether longer or different treatments could offer better protection.
The findings support a growing emphasis on early detection and intervention—aiming to prevent irreversible joint damage before it occurs.
If you’re interested in arthritis, consider exploring studies on natural remedies like extra virgin olive oil or pomegranate, which show potential benefits for managing rheumatoid arthritis.
For more insights, look into recent research on living pain-free with arthritis and how options like medical cannabis may help alleviate arthritis and back pain.
Source: King’s College London.